06/17/2026
Dr. Patrick Soon-Shiong is a billionaire physician-scientist, entrepreneur, and the founder of ImmunityBio. Throughout his career, he has focused on developing innovative treatments aimed at helping the body's own immune system fight disease. One of his most notable developments is Anktiva (N-803), an immunotherapy designed to support the body's natural defenses against c@ncer.
Unlike traditional treatments that often rely heavily on chemotherapy, Anktiva was developed with a different approach. Instead of directly attacking c@ncer cells with powerful chemicals, the therapy works by stimulating key parts of the immune system. Its goal is to help the body recognize and respond to abnormal cells more effectively.
Anktiva functions as an IL-15 receptor superagonist, a technology designed to activate and strengthen important immune cells. Among these are Natural Killer (NK) cells, which serve as one of the body's first lines of defense. These cells constantly patrol the body, searching for infected, damaged, or abnormal cells that may pose a threat. When activated, NK cells can identify and destroy c@ncerous cells before they spread further.
The therapy also enhances the activity of cytotoxic T-cells, another critical component of the immune system. These specialized cells are responsible for locating and eliminating cells that have become harmful. By boosting both NK cells and cytotoxic T-cells, Anktiva aims to strengthen the body's natural ability to target c@ncer cells.
This approach reflects a broader shift in modern medicine toward immunotherapy, where treatments are designed to work with the immune system rather than relying solely on conventional methods. Researchers believe that empowering the body's own defenses may offer new possibilities for treating certain forms of c@ncer while reducing dependence on more aggressive therapies.
Dr. Soon-Shiong's work has attracted worldwide attention because it focuses on harnessing the immune system's natural capabilities. His vision is based on the idea that the body's defense network already possesses powerful tools for fighting disease and that advanced therapies can help unlock that potential.
Today, Anktiva is recognized as one of the notable developments in the field of immunotherapy. Its focus on activating Natural Killer cells and cytotoxic T-cells represents a different strategy in the ongoing effort to improve c@ncer treatment and expand the options available to patients around the world.